---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-126731"
form_type: "8-K"
ticker: "CABA"
cik: "0001759138"
company_name: "Cabaletta Bio, Inc."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:33:02.853044+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cabaletta Bio Q3 2024: cash $183M, 40 U.S. sites recruiting; EMA greenlights lupus trial

## Summary
- R&D expenses $26.3M (up 91% YoY); G&A $6.8M (up 39%); cash $183.0M expected to fund ops into H1 2026.
- 16 patients enrolled, 10 dosed across RESET program as of Nov 12; 40 U.S. clinical sites actively recruiting.
- EMA allowed CTA for RESET-SLE trial in Europe; myositis, lupus, scleroderma data presented at ACR weekend.
- Gerwin Winter appointed SVP Head of International; Nicolette Sherman named CHRO replacing retiring Martha O'Connor.
- Investor call Nov 18 to review ACR data; Jefferies London conference Nov 20.

## SEC filing metadata
- accession: 0000950170-24-126731
- form_type: 8-K
- ticker: CABA
- cik: 0001759138
- company_name: Cabaletta Bio, Inc.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759138/000095017024126731/0000950170-24-126731-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759138/000095017024126731/caba-20241114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-126731
- JSON: https://secwatch.observer/filing/0000950170-24-126731.json
- Plain text: https://secwatch.observer/filing/0000950170-24-126731.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.